Advertisement
Advertisement
U.S. markets open in 7 hours 45 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BioLineRx Ltd. (BLRX.TA)

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
Add to watchlist
60.00+0.70 (+1.18%)
At close: 5:24PM IDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close59.30
Open59.80
Bid59.90 x 255900
Ask60.00 x 42900
Day's Range59.40 - 61.70
52 Week Range33.50 - 136.00
Volume1,319,192
Avg. Volume717,556
Market Cap42.569B
Beta (5Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)-0.07
Earnings DateNov 22, 2021 - Nov 26, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BLRX.TA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization

      BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). The study was performed by the Globa

    • Insider Monkey

      11 Best Stocks for Long Term Growth

      In this article, we discuss the 11 best stocks for long-term growth. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Stocks for Long Term Growth. As the economy recovers post COVID-19, many investors see the surge in consumer spending and the expansion of the digital economy […]

    • PR Newswire

      BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update

      BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2021 and provides a corporate update.

    Advertisement
    Advertisement